For the BRCA1 (BRCA2) group, the probability that CE MRI and mammography combined would be cost-effective would be 0.57 (0.82) and 0.71 (0.96) for a decision maker's willingness to pay per cancer detected of £20 000 and £30 000 respectively. The gene discussed is BRCA1; the disease is cancer.